NeuBase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on Huntington's Disease and Myotonic Dystrophy, and dominant genetic disorders